1 Introduction to Research & Analysis Reports
1.1 Primary Immunodeficiency Therapeutic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Primary Immunodeficiency Therapeutic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Primary Immunodeficiency Therapeutic Overall Market Size
2.1 Global Primary Immunodeficiency Therapeutic Market Size: 2022 VS 2029
2.2 Global Primary Immunodeficiency Therapeutic Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Primary Immunodeficiency Therapeutic Players in Global Market
3.2 Top Global Primary Immunodeficiency Therapeutic Companies Ranked by Revenue
3.3 Global Primary Immunodeficiency Therapeutic Revenue by Companies
3.4 Top 3 and Top 5 Primary Immunodeficiency Therapeutic Companies in Global Market, by Revenue in 2022
3.5 Global Companies Primary Immunodeficiency Therapeutic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Players in Global Market
3.6.1 List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies
3.6.2 List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Primary Immunodeficiency Therapeutic Market Size Markets, 2022 & 2029
4.1.2 Immunoglobulin Replacement Therapy
4.1.3 Stem Cell or Bone Marrow Transplantation
4.1.4 Antibiotic Therapy
4.1.5 Gene Therapy
4.1.6 Others
4.2 By Type – Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
4.2.1 By Type – Global Primary Immunodeficiency Therapeutic Revenue, 2018-2023
4.2.2 By Type – Global Primary Immunodeficiency Therapeutic Revenue, 2024-2029
4.2.3 By Type – Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Primary Immunodeficiency Therapeutic Market Size, 2022 & 2029
5.1.2 Antibody Deficiency
5.1.3 Cellular Immunodeficiency
5.1.4 Innate Immune Disorders
5.1.5 Others
5.2 By Application – Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
5.2.1 By Application – Global Primary Immunodeficiency Therapeutic Revenue, 2018-2023
5.2.2 By Application – Global Primary Immunodeficiency Therapeutic Revenue, 2024-2029
5.2.3 By Application – Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Primary Immunodeficiency Therapeutic Market Size, 2022 & 2029
6.2 By Region – Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
6.2.1 By Region – Global Primary Immunodeficiency Therapeutic Revenue, 2018-2023
6.2.2 By Region – Global Primary Immunodeficiency Therapeutic Revenue, 2024-2029
6.2.3 By Region – Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.3.2 US Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.3.3 Canada Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.3.4 Mexico Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.4.2 Germany Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.3 France Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.4 U.K. Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.5 Italy Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.6 Russia Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.7 Nordic Countries Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.4.8 Benelux Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.5.2 China Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5.3 Japan Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5.4 South Korea Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5.5 Southeast Asia Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.5.6 India Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.6.2 Brazil Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.6.3 Argentina Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, 2018-2029
6.7.2 Turkey Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.7.3 Israel Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.7.4 Saudi Arabia Primary Immunodeficiency Therapeutic Market Size, 2018-2029
6.7.5 UAE Primary Immunodeficiency Therapeutic Market Size, 2018-2029
7 Primary Immunodeficiency Therapeutic Companies Profiles
7.1 Baxter International
7.1.1 Baxter International Company Summary
7.1.2 Baxter International Business Overview
7.1.3 Baxter International Primary Immunodeficiency Therapeutic Major Product Offerings
7.1.4 Baxter International Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.1.5 Baxter International Key News & Latest Developments
7.2 Takeda Pharmaceutical
7.2.1 Takeda Pharmaceutical Company Summary
7.2.2 Takeda Pharmaceutical Business Overview
7.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Major Product Offerings
7.2.4 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.2.5 Takeda Pharmaceutical Key News & Latest Developments
7.3 CSL Limited
7.3.1 CSL Limited Company Summary
7.3.2 CSL Limited Business Overview
7.3.3 CSL Limited Primary Immunodeficiency Therapeutic Major Product Offerings
7.3.4 CSL Limited Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.3.5 CSL Limited Key News & Latest Developments
7.4 Octapharma
7.4.1 Octapharma Company Summary
7.4.2 Octapharma Business Overview
7.4.3 Octapharma Primary Immunodeficiency Therapeutic Major Product Offerings
7.4.4 Octapharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.4.5 Octapharma Key News & Latest Developments
7.5 Kedrion Biopharma
7.5.1 Kedrion Biopharma Company Summary
7.5.2 Kedrion Biopharma Business Overview
7.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Major Product Offerings
7.5.4 Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.5.5 Kedrion Biopharma Key News & Latest Developments
7.6 Bio Products Laboratory
7.6.1 Bio Products Laboratory Company Summary
7.6.2 Bio Products Laboratory Business Overview
7.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Major Product Offerings
7.6.4 Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.6.5 Bio Products Laboratory Key News & Latest Developments
7.7 LFB group
7.7.1 LFB group Company Summary
7.7.2 LFB group Business Overview
7.7.3 LFB group Primary Immunodeficiency Therapeutic Major Product Offerings
7.7.4 LFB group Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.7.5 LFB group Key News & Latest Developments
7.8 Grifols
7.8.1 Grifols Company Summary
7.8.2 Grifols Business Overview
7.8.3 Grifols Primary Immunodeficiency Therapeutic Major Product Offerings
7.8.4 Grifols Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.8.5 Grifols Key News & Latest Developments
7.9 Lupin Pharmaceuticals
7.9.1 Lupin Pharmaceuticals Company Summary
7.9.2 Lupin Pharmaceuticals Business Overview
7.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Major Product Offerings
7.9.4 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue in Global Market (2018-2023)
7.9.5 Lupin Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Table 1. Primary Immunodeficiency Therapeutic Market Opportunities & Trends in Global Market
Table 2. Primary Immunodeficiency Therapeutic Market Drivers in Global Market
Table 3. Primary Immunodeficiency Therapeutic Market Restraints in Global Market
Table 4. Key Players of Primary Immunodeficiency Therapeutic in Global Market
Table 5. Top Primary Immunodeficiency Therapeutic Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Primary Immunodeficiency Therapeutic Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Primary Immunodeficiency Therapeutic Revenue Share by Companies, 2018-2023
Table 8. Global Companies Primary Immunodeficiency Therapeutic Product Type
Table 9. List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Primary Immunodeficiency Therapeutic Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Primary Immunodeficiency Therapeutic Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2024-2029
Table 30. Baxter International Company Summary
Table 31. Baxter International Primary Immunodeficiency Therapeutic Product Offerings
Table 32. Baxter International Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 33. Baxter International Key News & Latest Developments
Table 34. Takeda Pharmaceutical Company Summary
Table 35. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product Offerings
Table 36. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 37. Takeda Pharmaceutical Key News & Latest Developments
Table 38. CSL Limited Company Summary
Table 39. CSL Limited Primary Immunodeficiency Therapeutic Product Offerings
Table 40. CSL Limited Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 41. CSL Limited Key News & Latest Developments
Table 42. Octapharma Company Summary
Table 43. Octapharma Primary Immunodeficiency Therapeutic Product Offerings
Table 44. Octapharma Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 45. Octapharma Key News & Latest Developments
Table 46. Kedrion Biopharma Company Summary
Table 47. Kedrion Biopharma Primary Immunodeficiency Therapeutic Product Offerings
Table 48. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 49. Kedrion Biopharma Key News & Latest Developments
Table 50. Bio Products Laboratory Company Summary
Table 51. Bio Products Laboratory Primary Immunodeficiency Therapeutic Product Offerings
Table 52. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 53. Bio Products Laboratory Key News & Latest Developments
Table 54. LFB group Company Summary
Table 55. LFB group Primary Immunodeficiency Therapeutic Product Offerings
Table 56. LFB group Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 57. LFB group Key News & Latest Developments
Table 58. Grifols Company Summary
Table 59. Grifols Primary Immunodeficiency Therapeutic Product Offerings
Table 60. Grifols Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 61. Grifols Key News & Latest Developments
Table 62. Lupin Pharmaceuticals Company Summary
Table 63. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product Offerings
Table 64. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue (US$, Mn) & (2018-2023)
Table 65. Lupin Pharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Primary Immunodeficiency Therapeutic Segment by Type in 2022
Figure 2. Primary Immunodeficiency Therapeutic Segment by Application in 2022
Figure 3. Global Primary Immunodeficiency Therapeutic Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Primary Immunodeficiency Therapeutic Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Primary Immunodeficiency Therapeutic Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Primary Immunodeficiency Therapeutic Revenue in 2022
Figure 8. By Type - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 9. By Application - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 10. By Type - Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 12. By Application - Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 14. By Region - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 15. By Country - North America Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 16. US Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 20. Germany Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 21. France Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 28. China Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 32. India Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 34. Brazil Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue Market Share, 2018-2029
Figure 37. Turkey Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2018-2029
Figure 41. Baxter International Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. CSL Limited Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Octapharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. LFB group Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Grifols Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
